Use of elexacaftor-texacaftor-ivacaftor ("ETI"), also known as Trikafta, is associated with weight gain in most people with cystic fibrosis (CF) who take this medication.
Dr. Ren's primary research focus is to develop better methods to assess lung disease in infants and young children using advanced pulmonary function testing and imaging.
The Children’s Hospital of Philadelphia is seeking healthy adolescents and young adults ages 16-22 years old, to participate in the Muscle Accrual in Cystic Fibrosis Research Study.
The purpose of this research study is to examine and understand the various mechanisms that contribute to Cystic Fibrosis Related Diabetes and gain a better understanding of potential means to treat Cystic Fibrosis Related Diabetes.
The purpose of this research study is to examine and understand the various mechanisms that contribute to CFRD and gain a better understanding of potential means to treat CFRD.
The goal of the study extension is to see whether the incretin hormone GIP increases insulin secretion in individuals with CF and normal glucose tolerance compared to individuals without CF and normal glucose tolerance.
Focusing on the underpinnings of progressive insulin secretion defects and worsening glucose tolerance in children and adults with cystic fibrosis, and examining the links between hyperglycemia and insulin deficiency and cystic fibrosis-related outcomes.
